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Background: The present study aimed to elucidate the relationship between 
microvessel count (MVC) according to CD34 expression and prognosis in intrahepatic 
cholangiocarcinoma (ICC) patients who underwent hepatectomy based on our 
preliminary study.  
Methods: Relationships between MVC and clinicopathological factors were examined 
in 37 ICC patients. CD34 expression was analyzed using immunohistochemical 
methods.  
Results: Median MVC for ICC patients was 140/mm2, which was applied as a cut-off 
value. Lower MVC was significantly associated with larger tumor size, periductal 
infiltrating type, and advanced Japanese Tumor-Node-Metastasis stage (p<0.05). 
Univariate survival analysis identified higher carcinoembryonic antigen level, 
peri-ductal infiltrating type, poor histological differentiation and lower MVC as 
significantly associated with lower 5-year survival rates. The 5-year survival rate in the 
higher MVC group was significantly greater than that in the lower MVC group (44 vs 
7%, p=0.048). According to Cox multivariate survival analysis, only periductal 
infiltrating type on macroscopic examination was identified as a significant independent 
risk factor for poor survival after hepatectomy (risk ratio, 4.8; p=0.006), not MVC (1.1; 
p=0.82).  
Conclusion: Tumor MVC might offer a useful prognostic marker of ICC patient 
survival after hepatectomy and further investigation in a larger series is warranted. 
 




Microvessel counts according to CD34 expression representing tumor angiogenesis 
offer a candidate prognostic factor in intrahepatic cholangiocarcinomas to predict tumor 
recurrence and poorer patient survival, but not an independent factor in multivariate 
analysis.  
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Hepatic resection is currently the only curative option for radical treatment of 
intrahepatic cholangiocarcinoma (ICC). However, the recurrence rate after resection 
remains high and patient survival is thus unsatisfactory. 1,2 Although some conventional 
clinicopathological factors and surgical margins in ICC have been shown to be related 
to tumor relapse and shorter patient survival, 3-5 accurate prediction of prognosis for ICC 
is currently impossible. The examination of differences in biological characteristics of 
tumors may provide useful information on the activity of ICC. According to recent 
reports, candidates for tumor biological factors and molecular markers in ICC patients 
include chromosomal aberration, 6 lymphatic microvessels, 7 adhesion molecules, 8 
mucin expression, 9 Expression of matrix metalloproteinase, 10 expression of 
cyclooxygenase-2, 11 and CD24 expression. 12 Combining the use of conventional 
clinicopathological factors and prognostic factors from tumor biology may improve the 
prediction of prognosis after hepatectomy for ICC and may contribute to a predictive 
staging classification. The recent American loint Committee on Cancer/Union Internatic 
nale Contre le Cancer (AICC/UICC) staging is inadequate for predicting patient 
survival. 13 A combination of conventional clinicopathologic factors and tumor 
biological factors may thus improve predictions of prognosis after hepatectomy for ICC. 
Tumor angiogenesis seems likely to be important for supporting tumor growth in 
general, 14and ICC also expresses some angiogenic factors such as vascular endothelial 
growth factor (VEGF). 15 Levels of these angiogenic factors might affect patient 
survival and microvessel density (MVD) is known to correlate with tumor 
aggressiveness and prognosis in ICC by Shirabe et al. 16 We have provided preliminary 
results of higher microvessel count (MVC), using CD34 antibody as a marker, 
associated with poor prognosis in ICC patients undergoing hepatic resection for 32 
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months. 17 However, the utility of this marker has yet to be fully elucidated. ICC is 
typically a hypovascular tumor, based on imaging diagnosis, and has very poor survival 
compared to other digestive diseases. 18 In such tumors, the above theory with respect to 
tumor angiogenesis does not always apply. Our recent study showed that hypovascular 
image findings on computed tomography were associated with patient outcomes after 
operation.19 Thus, although few recent reports have shown relationships between MVD 
and postoperative outcomes in ICC patient, 20 the clinical impacts of these relationships 
have yet to be fully clarified. Based on our study of MVD in hepatocellular carcinoma 
and metastatic liver carcinoma, 21, 22 we have hypothesized that tumor vascularity in ICC 
represents a factor associated with tumor growth and invasion, thus causing poor 
prognosis that MVC may play a significant role in liver tumor progression. 
The present study examined relationships between MVC in ICC using 
immunohistochemical staining and conventional clinicopathological factors, and 
prognosis in ICC patients with a longer follow-up period (5 years) with 18 months of 
minimum follow-up period and 28 moths of median follow-up period to clarify our 
hypothesis. 
 
MATERIALS AND METHODS 
Patients 
A total of 37 consecutive patients (20 men, 17 women) with ICC who were 
admitted to the Division of Surgical Oncology in the Department of Translational 
Medical Sciences at Nagasaki University Graduate School of Biomedical Sciences 
(NUGSBS) between January 2002 and April 2007 (minimum follow-up, 18 months) 
were analyzed retrospectively in this study. Data were retrieved from both anesthetic 
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and patient charts, plus the NUGSBS database, to cover the period of hospitalization 
following hepatectomy. The study design was approved by the Ethics Review Board of 
our institute and signed consent for clinical research using tissue or blood samples was 
obtained from each patient. After surgery, no patients routinely received adjuvant 
chemotherapy in the early postoperative period. Follow-up included measurement of 
serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) every 
3 months and abdominal CT and chest X-ray every 3 to 6 months. When recurrence was 
detected, patients received chemotherapy (intravenous infusion or oral intake of 
anticancer drugs such as Gemcitabone (Gemzar®; Eli Lilly Co., IN) and Tegafur- 
Gimeracil - Oteracil Potassium (TS-1; TAIHO Phamaceutical Co., Ltd., Tokyo, Japan)). 
Indocyanine green retention rate at 15 min (ICGR15) was routinely examined to 
define the preoperatively functional liver reserve. The volume of liver to be resected 
was determined preoperatively based on the results of ICGR15 and the estimated 
resected liver volume, excluding tumor volume, as measured by the computed 
tomography volumetry. 23 Liver activity as measured using technetium-99m galactosyl 
human serum albumin (99mTc-GSA) scintigraphy at 15 min after injection 23 and other 
liver functional parameters were also evaluated before surgery. All 37 patients 
underwent hepatic resection, with surgical procedures including segmentectomy (n=3), 
sectoriectomy (n=17), right or left hepatectomy (n=14), and extended hepatectomy 
(n=3). All hepatic tumors were resected without macroscopic exposure of the amputated 
section to the remaining liver. Pathological and morphological parameters, and Japanese 
Tumor-Node-Metastasis (TNM) stage were used as defined by the Liver Cancer Study 




Resected specimens were fixed in 10% formalin and embedded in paraffin. Thin 
sections (4 μm) were deparaffinized twice using xylene and rehydrated in ethanol series 
(100%, 90% and 80%). Sections were placed in 0.01 mol/L of trisodium citrate 
dehydrate buffer (pH 6.0), then treated in a microwave oven for 10 min at 500 W. For 
CD34 staining, 25 tissue sections were digested with 0.2% trypsin in 0.01 mol/L 
phosphate-buffered saline (PBS) for 20 min at 37C. In the next step, tissues were 
immersed in 3% H2O2 with distilled water for 10 min to inactivate endogenous 
peroxidases. After blocking non-specific binding by normal goat serum, sections were 
incubated overnight at 4C with mouse anti-monoclonal CD34 antibody (1:25, 
QB-END/10; Novocastra Laboratories, Newcastle, UK) as the primary antibody. This 
was followed by reaction with biotinylated anti-immunoglobulin and reagent using 
labeled streptavidin-biotin (LSAB) kit peroxidase (Dako, Carpinteria, CA). The 
peroxidase reaction was visualized with 0.01% H2O2 and 3,3'-diaminobenzidine under 
light microscopy (200). For MVC using CD34 staining, average count was determined 
for the 5 most-vascular areas in the CCC examined under 200 magnification. Each 
slide was assessed by 2 pathologists blinded to patient data. Figure 1A and B show the 
high and low MVC, respectively.  
 
Statistical analysis 
Continuous data are expressed as mean ± standard deviation. Data from different 
groups were compared using one-way analysis of variance and examined with Student 
t-test or the Dunnett multiple comparison test. For univariate analysis, categorical data 
were analyzed using the Fisher exact test. Disease-free and overall survival rates were 
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calculated according to the Kaplan-Meier method, and differences between groups were 
tested for significance using the log-rank test. Multivariate analysis was performed 
using proportional hazards regression modeling, despite the limited number of subjects. 
Two-tailed values of p<0.05 were considered statistically significant. All statistical 
analyses were performed using SAS software (Statistical Analysis System, Cary, NC). 
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RESULTS 
Among the 37 patients in the present study, overall 1-, 3- and 5-year survival rates 
were 51%, 35% and 27%, respectively, and median overall survival was 48 months. 
Disease-free 1-, 3- and 5-year survival rates were 45%, 17% and 6%, respectively, and 
median disease-free survival was 29 months. A total of 26 patients (70.3%) displayed 
tumor recurrence after hepatectomy, which were liver metastasis in 9, local recurrence 
in 6, peritoneal dissemination in 8, lymph node metastasis in 4 and bone in one (dual 
recurrence in two patients). 
Median MVC within the tumor area was 140/mm2 (51-363/mm2), and this value was 
applied as a cut-off value. Table I shows the relationship between MVC and 
clinicopathological features. Chronic viral hepatitis tended to be more frequent in the 
higher MVC group (≥140/mm2). Size ≥5 cm, peri-ductal infiltrating type and advanced 
TNM stage (III) were significantly more frequent in the lower MVC group than in the 
higher MDC group. Postoperative tumor recurrence tended to be more frequent in the 
lower MDC group than in the higher MDC group but not significant. However, MVC 
was not different between types of recurrence. Table II shows the relationship between 
overall survival and clinicopathological factors including MVC. Higher 
carcinoembryonic antigen (CEA) level, peri-ductal infiltrating type on macroscopic 
examination, poor histological differentiation and lower MVC were significantly 
associated with lower 5-year survival rate. In addition, nodal status, tumor size, and 
intraoperative blood loss tended to be associated with overall survival. Figure 2 shows 
that survival was better in the higher MVC group than in the lower MVC group. By 
applying these prognostic parameters, multivariate analysis for overall survival after 
hepatectomy was performed even though the number of subjects was limited in the 
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present study (Table III). Only the macroscopic finding of periductal infiltrating type, 
not MVC, was identified as a significant independent risk factor for poor overall 




Clear prognostic factors, other than pathological factors such as nodal status, tumor 
size or number and vascular involvement, have not been clarified for ICC and the 
significance of the present Japanese Tumor-Node-Metastasis staging remains 
controversial. Various angiogenic factors in ICC have been reported as candidate 
prognostic marker in recent years. 14-16, 20 In both the preliminary and present studies, 
we focused on MVC for liver malignancies, including ICC. 17 This parameter can be 
conventionally and easily examined using immunohistochemistry at any institute, and 
we propose the inclusion of this examination in conventional pathological diagnosis to 
predict tumor malignancy. Our preliminary study and other studies have revealed that 
tumor angiogenesis might be related to patient prognosis in ICC patients who undergo 
radical hepatectomy, although results have not been similar between investigators. 16,20 
Our previous study examined the usefulness of MVC for predicting outcomes in ICC 
patients and we have thus waited for 5 years since the first report to determine the 
relationship with a longer period after treatment. 
In the present study, MVC <140/mm2 tended to be associated with the status of 
chronic viral hepatitis, primarily hepatitis C. According to previous reports, some ICCs 
occur in patients with chronic hepatitis, but not with biliary diseases. 26 Our previous 
report with respect to the enhancement pattern of the ICC, indicated that some ICC 
showed hypervascularity on computed tomography (CT) in patients with concomitant 
chronic viral hepatitis. 19 As MVC reflects tumor vascularity, the present result is 
plausible. Chronic viral hepatitis may be associated with carcinogenesis of ICC such as 
a mass-forming type.27 Lower MVC, on the other hand, related to progression of tumor 
malignancy in the present results. Basically, ICC showed a characteristic of 
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hypovascularity on imaging analysis.28 ICC is a devastating malignancy that is 
notoriously difficult to diagnose, but with increasing incidence worldwide. 29 Current 
imaging modalities such as CT and magnetic resonance imaging (MRI) provide useful 
diagnostic information, as imaging analysis is important in defining the indications for 
surgery.30 The predominant radiological characteristic of ICC is hypovascular or 
marginal enhancement (ring enhancement) of the mass lesion, with or without 
peripheral biliary dilatation or segmental liver atrophy. 31 However, tumor morphology 
and vascularity show different characteristics in some cases.32 Imaging findings on 
enhanced CT or positron emission tomography 33 were also related to patient outcomes. 
According to these findings, tumor vascularity may be increased according to tumor 
progression for limited growth of ICC. By reflecting a correlation between MVC and 
tumor malignancy, however, the lower MVC also tended to be related to postoperative 
tumor recurrence in the present study. Our present results demonstrate that a greater 
blood supply is not always associated with more aggressive tumor behavior. Even in 
hepatocellular carcinoma as a representative hypervascular tumor, patients with lower 
MVC carcinomas showed a poor prognosis.22 Tumor angiogenesis is undoubtedly an 
important factor for tumor growth; however, other factors may be closely related to 
tumor invasiveness. 34 Lower tumor vascularity may lead to anti-cancer treatment 
resistance via intra-hepatic blood flow.35 Further study needs to clarify relationships 
between angiogenic parameters and specific clinicopathological findings. 
The goal of this study was to clarify the relationship between MVC and 
postoperative survival in ICC patients. In survival analysis, several associated 
parameters including MVC were revealed by univariate survival analysis. Predictive 
factors for patient prognosis have been proposed by many investigators, but no 
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consensus has yet been reached.20,36 The present study showed that lower MVC was 
significantly related to shorter survival after surgery, unlike the results of previous 
reports. 16,20,36 However, our previous study of tumor enhancement pattern showed that 
a hypovascular pattern was related to poorer survival, 19 so the present result seems 
reasonable. In our preliminary report, a significant correlation between MVC and 
patient survival in ICC was not observed and, therefore, longer patient follow-up or a 
larger size study in collaboration with other institutions is necessary when dealing with 
rare tumors such as ICC. Higher MVC clearly does not always correlate with malignant 
behavior of carcinomas. A similar study we performed in hepatocellular carcinomas also 
showed that lower MVC was associated with poor patient outcomes. 22 Tumor 
angiogenesis may be necessary for the growth of liver tumors in earlier stages, 37 but 
this influence might be reduced during the acquisition of treatment resistances such as 
fibrosis in ICC. As shown in the survival curve, the drop in the survival curve was 
similar between higher and lower MVC within 1 year after hepatectomy. Only 6 ICC 
patients showed long-term survival exceeding 1 year after surgery. Given this result, 
tumor recurrence and failure of survival might occur regardless of whether ICC displays 
higher MVC. Some reports have shown that the expression of angiogenic factors or 
higher MVC are associated with tumor malignancy or poor patient survival, 16 while 
others have shown no relationship with survival in ICC patients. 20,36 The influences of 
angiogenic factors thus might not be particularly strong. Under multivariate analysis, 
only macroscopic findings were identified as a strong independent prognostic factor, 
with other candidate factors including MVC not showing any significance. We also 
performed the same survival analysis after excluding this strong contributing factor, but 
this failed to identify any significant independent factors predictive of poor survival. 
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ICC is a malignant tumor originating in the intrahepatic bile duct, and comprises cells 
that mostly resemble those of the peripheral bile ducts. 38 However, ICC is not always 
uniform, and is classified into subgroups according to macroscopic findings, with the 
clinical and pathological characteristics and prognosis differing significantly among 
subgroups. 39 Diagnosis of ICC subtype would be useful in predicting prognosis or 
selecting adjuvant treatments with hepatic resection. 
Further investigation in a larger population of ICC patients is needed to resolve 
the problem of whether tumor angiogenesis offers a useful predictor of patient survival. 
As ICC is not a common disease, a nationwide comprehensive study to investigate 
various candidate factors is necessary. When determining the specific prognostic factors 
of carcinoma cells, we must eventually consider strategies for additional anti-angiogenic 
treatments after hepatectomy. At this stage, some anti-angiogenic drugs have been 
developed in the field of ICC, but they are not yet clinically applicable. 20 
In conclusion, the present study examined the relationship between MVC 
according to CD34 expression and overall survival in ICC patients. As a tumor 
biological factor, MVC representing tumor angiogenesis might offer a candidate 
prognostic factor in ICC to predict tumor recurrence and poorer patient survival, but not 
an independent factor in multivariate analysis. Further study in a larger population of 
ICC patients undergoing surgical resection is warranted to clarify the role of tumor 
angiogenesis in this disease. 
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Fig.1. Representative figures of microvessels around the metastatic liver tumor. Cases 







Fig. 2.  Relationship between MVC and overall survival in ICC patients who 
underwent hepatic resection. The solid line shows survival in patients with higher MVC 
and the dotted line shows survival in patients with lower MVC. 
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TABLE 1. Correlations between tumor microvessel counts and clinicopathologic parameters or 
postoperative recurrence rate in intrahepatic cholangiocarcinomas 
 Microvessel counts P value 




Age,  ≥60 years 
Chronic viral hepatitis,   Yes 
Serum tumor marker 
   CEA ≥5 ng/ml 
   CA19-9  ≥37 U/ml 
   AFP   ≥100 ng/ml 
Tumor size,   ≥5 cm 
Macroscopic finding §  
Mass-forming type 
Peri-ductal infiltrating type 
Intra-ductal growth 
Histological differentiation 
   Well 
Moderately 
Poorly 
Intrahepatic metastasis,    Yes 
Lymph node metastasis,    Yes 
Tumor-node-metastasis stage ¶ 
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Parenthesis shows a percentage. 
CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen19-9, AFP: alpha-feto protein,  
§Macroscopic classification of intrahepatic cholangiocarcinoma,24 ¶ Japanese TNM stage by 
classification of intrahepatic cholangiocarcinoma24 
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TABLE 2.  Relationship between clinicopathological factors and survival rates in 
intrahepatic cholangiocarcinoma 
 Overall survival rates (5years:%) P value 
Gender 
  Male 
Female 
Age (years) 
  >60 
≤60  
Chronic viral hepatitis  
  No 
Yes 
Preoperative CEA (ng/ml) 






Node status of primary cancer 





Size of tumor (mm) 
  <50 
≥50 
Histological differentiation 
  Well 
Moderately 
Poorly 
Microvessel counts, CD34(/mm2) 
  <140 
≥140 
Intraoperative blood loss (ml) ¶ 







































































CEA: carcinoembryonic antigen 
MF, mass-forming; IG, intraductal growth; PDI, peri-ductal infiltrating 
¶ n=19 in case of blood loss≥1000ml
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TABLE 3.  Multivariate analysis by Cox’s proportional hazard test of prognostic 
factors influencing overall survival in intrahepatic cholangiocarcinomas after 
hepatectomy 
 
 Overall survival 
Risk ratio 95%CI p 
Preoperative CEA level 
    <10 ng/ml vs ≥10 ng/ml 
Tumor size 
    <5cm vs  ≥5cm 
Macroscopic finding 
MF/IG vs PDI 
Pathological differentiation 
    Well vs  Moderately/Poorly 
Node metastasis of primary cancer 
  Negative vs  Positive 
Blood loss 
    <1000ml vs  ≥1000ml 
Microvessel counts by CD34 











































MF, mass-forming; IG, intraductal growth; PDI, peri-ductal infiltrating 
 
